Bolton Securities’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-26,000
Closed -$379K – 2333
2026
Q2
$379K Buy
26,000
+18,000
+225% +$319K 0.01% 681
2026
Q1
$152K Hold
8,000
– – 0.01% 892
2025
Q4
$140K Hold
8,000
– – 0.01% 888
2025
Q3
$165K Buy
+8,000
New +$194K 0.01% 796

Other funds holding SMMT

Bolton Securities's SMMT Position: Q3 2026 in Review

Bolton Securities sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 26,000 shares — an estimated $379K sold.

Bolton Securities first reported a position in SMMT in Q3 2025 and held it in 4 quarters. The position peaked at $379K in Q2 2026. 295 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Bolton Securities reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Bolton Securities sold 26,000 Summit Therapeutics shares in Q3 2026, an estimated $379K.
  • Bolton Securities first reported a position in Summit Therapeutics in Q3 2025 and held it in 4 quarters.
  • Bolton Securities's Summit Therapeutics position peaked at $379K in Q2 2026.
  • 295 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Bolton Securities's 13F filing for Q3 2026, filed 12 Nov 2026.